Episode
Why Tata 1mg thinks speed is the wrong bet in pharma
- Podcast
- Daybreak
- Published
- Aug 19, 2026
- Duration seconds
- 702
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/a8070683
Actions
POST https://stenobird.com/v1/public/podcasts/daybreak-5886514/episodes/why-tata-1mg-thinks-speed-is-the-wrong-bet-in-pharma/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/daybreak-5886514/why-tata-1mg-thinks-speed-is-the-wrong-bet-in-pharma.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Tata 1mg just reported revenue of nearly 3,000 crore rupees for the last financial year, roughly ten times what it earned when Tata took control, and it is turning a profit while much of the sector bleeds cash. In an e-pharmacy market obsessed with 10-minute delivery and deep discounts, 1mg won by doing the opposite. It capped its discounts and built its own labs and supply chain, and it treats fast delivery as a minor add-on. In this episode, we unpack why patience beats blitzscaling in Indian healthcare and what 1mg means when it calls healthcare longitudinal. Take The Great Rewiring survey here Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.